MedTrace Logo

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

NCT00003126 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-01-04

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).

Conditions

Interventions

DRUG

Interleukin-2

High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC

Sponsors & Collaborators

  • Chiron Corporation

    collaborator INDUSTRY

  • Loyola University

    lead OTHER

Principal Investigators

  • Joseph I. Clark, MD · Loyola University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30
Primary Completion
2002-08-31
Completion
2002-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003126 on ClinicalTrials.gov